Moderna, inc. (MRNA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Revenue:
Total revenue

8,389

14,055

17,046

13,083

16,025

35,421

41,757

28,851

29,039

Operating expenses:
Research and development

115,137

117,685

119,715

128,496

130,413

150,429

109,050

104,479

90,124

General and administrative

24,114

25,656

28,188

28,523

27,253

38,023

18,525

21,387

16,317

Total operating expenses

139,251

143,341

147,903

157,019

157,666

188,452

127,575

125,866

106,441

Loss from operations

-130,862

-129,286

-130,857

-143,936

-141,641

-153,031

-85,818

-97,015

-77,402

Interest income

7,852

7,984

9,252

10,322

10,972

8,894

6,519

6,401

5,209

Other expense, net

-1,154

-2,064

-1,767

-1,764

-1,931

2,879

-1,032

171

-183

Loss before income taxes

-124,164

-123,366

-123,372

-135,378

-132,600

-141,258

-80,331

-90,443

-72,376

Provision for (benefit from) income taxes

66

-169

-178

-324

-24

168

0

158

0

Net Income (Loss) Attributable to Parent

-124,230

-123,176

-123,194

-135,054

-132,576

-141,392

-80,331

-90,601

-72,376

Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Net loss attributable to common stockholders

-

-

-123,194

-135,054

-

-144,099

-87,819

-94,082

-75,857

Net loss per share, basic and diluted (usd per share)

-0.35

-0.37

-0.37

-0.41

-0.40

-1.04

-1.32

-1.43

-1.16

Weighted average common shares used in net loss per share, basic and diluted (in shares)

353,105

334,453

330,769

329,176

328,809

126,803

66,283

65,938

65,430

Collaboration revenue
Total revenue

3,187

10,046

9,614

9,842

13,301

19,732

16,935

19,742

20,110

Collaboration revenue from related party
Total revenue

1,270

-

-

-

814

-

-

-

-

Revenues

-

-

3,724

188

-

-

19,727

6,089

7,350

Grant revenue
Total revenue

3,932

3,502

3,708

3,053

1,910

2,862

5,095

3,020

1,579